RIGEL PHARMACEUTICALS INC — Director's Dealing 2025

Sep 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2025-09-15

Reporting Person: Santos David A (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-09-15	Employee Stock Option (right to buy)	$22.49	A	7394	Acquired	2035-01-29	Common Stock (7394)	Direct

Footnotes

F1: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met.

F2: The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met.